INTRODUCTION
Anticoagulation is a widespread therapeutic intervention as secondary prevention after various venous or arterial thrombotic or thromboembolic events, or as primary prophylaxis, especially of stroke or systemic embolism in patients with atrial fibrillation. More than 6 million people in Europe have atrial fibrillation [1] , with prevalence estimated from 1-2% [1] to 2.9% or more in adults [2] , and increasing with age. Long-term risk reduction of thrombotic or thromboembolic events can be achieved using vitamin K antagonists (VKA) and in Europe the most commonly used are acenocoumarol, phenprocoumon and warfarin. Treatment with these types of anticoagulants is very effective in reducing the risk of an ischemic stroke while maintaining a low risk of bleeding [3] . 
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Maintenance of INR within the therapeutic range with VKA is challenging for many patients. More frequent measurement of INR, which improves control of anticoagulant therapy, can be better achieved by the patient using a home-based INR monitoring device compared to outpatient visits to a laboratory or clinic [7, 8] . Two options of self-care are available to the patient: patient self-testing (PST), where the INR test is executed by the patient and the INR value is communicated with the patient's clinic, which responds with a new dosage schedule; and patient selfmanagement (PSM), where the patients are trained to monitor and interpret the INR themselves, and adjust the anticoagulant dose accordingly. Systematic reviews have shown PST and PSM to be superior to standard monitoring, with fewer thromboembolic events, decreased overall mortality and reduced bleeding events [7, [9] [10] [11] [12] . PST/PSM is therefore recommended in anticoagulant guidelines for suitable patients [13, 14] .
Effective PST or PSM requires not only able and motivated patients, a user-friendly, [8, 19, 20] . The current analysis aims to observe the clinical impact of the different INR measurement devices on the coagulation control parameters as well as on the overall clinical outcomes.
METHODS

Description of the NTS
The NTS was established in 2006 and has developed an extensive patient support service, comprised of e-learning, user-friendly, intelligent software, one-on-one instruction and education, 24/7 medical service desk, The first 90 days after treatment start were excluded from the observation period to allow for familiarization with the system (consistent with the analytical approach used elsewhere [8, 23] Comparing the effect on the TTR of the same set of patient characteristics across the two monitors using a univariate analysis, the overall difference in the effect of the two monitors was not statistically significant (P = 0.079) and only became statistically significant in defined subgroups (without a correction for multiple testing) ( Table 2 ). However, some differences were observed in the patient distribution among the two monitors, with INRatio2 being used disproportionally more often in males, patients
with an age of 45-74 years, patients with atrial fibrillation as a primary indication, patients with a target INR range of 2.5-3.5, and patients receiving phenprocoumon. To take these differences in distribution into account, a multivariate analysis was subsequently performed.
Clinical Events
Self-reported minor clinical events (Table 3) were infrequently recorded by patients, with a total of 4,043 minor events being reported in Table 3 ), although the number of events was low for both groups. Table 3 ). Consequently, the Kaplan-Meier estimation showed mostly identical curves (Fig. 1) . However, as the risk profile was different between these two populations, a multivariate analysis was subsequently performed for verification.
Multivariate Analysis for Surrogate Parameters
The multivariate analysis (Table 4) , considering all patient characteristics, only had a small 
Multivariate Analysis for Fatal Events
The multivariate Cox regression analysis for the different parameters on patient survival showed that the choice of the device had no statistically significant influence (HR 1.05, 95% CI 0.65-1.70, P = 0.838) (Fig. 1) . Similarly, most indications did not significantly influence the risk, while the target range and, most prominently, patient age at start, had statistically significant effects (a year higher age increased the HR by 8%, 95% CI 5-11%, P\0.001) (Fig. 2) . Since major clinical events and deaths could not be verifiably attributed to a particular cause in the NTS data, no analysis of the rate of individual major thrombotic or hemorrhagic events could be completed. Therefore, it is not possible to compare the overall rate in the NTS data with rates reported in studies of new oral anticoagulant agents (NOACs), nor is it an objective of this analysis. In addition, this analysis is based on data collected in clinical practice, and not in the pre-specified and more tightly defined setting of randomized controlled trials. The major NOAC studies in atrial fibrillation suggest a general non-inferiority of NOACs versus warfarin with a reduction of hemorrhagic events (most notably of cerebral bleeding [27] [28] [29] [30] ). Interestingly some metaanalyses found in subgroup analyses a dependency of this effect on the quality of TTR control in the VKA group. Gó mez-Outes et al. [28] found that the positive effects of NOACs versus warfarin on non-hemorrhagic strokes and systemic embolic events and on mortality were present in centers that only achieved a TTR below 65% in the warfarin arm. Similarly Ruff et al. [31] showed in a recent meta-analysis that there was a trend for a lower risk reduction of NOACs on stroke and systemic embolism as well as on major bleeding in centers that achieved a TTR of 66% or better (P of interaction 0.60 and 0.022, respectively).
As with any antithrombotic treatment, anticoagulation with VKA bears the risk of bleeding complications which are regarded as the main adverse event of anticoagulant treatment. In our analysis, minor bleeding complications were infrequently recorded with \1 event per patient-year. More than half of these events were bruises, which are generally without any clinical relevance, and nosebleeds. 3.94%/year [34] . The meta-analysis of Rose and colleagues [35] reported death rates of 2.3-8.1
per 100 patient-years based on 15 randomized controlled trials. Similarly, Heneghan et al. [12] found an average death rate of 3.9% while in self-monitoring this rate was reduced to 2.4%. It should be mentioned that the frequency in use of the CoaguChek XS and the INRatio2 did not differ significantly among patients experiencing fatal events, in either univariate or multivariate analysis. In the latter statistic approach, high target INR (3.0-4.0) and, most prominently, older age at the start of anticoagulation significantly influenced the risk, and 1 year of higher age increased the HR by 8%. Thus, self-testing was found to be efficient in reduction of fatal events, regardless of the monitor used for INR determination. Hugo Stoevelaar collected data and provided critical review and approval of the manuscript. Christoph Sucker drafted sections and provided critical review and approval of the manuscript.
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